Generic Miralax ( Polyethylene glycol 3350 )

Order cheap Generic Miralax (Polyethylene glycol 3350) without dr prescription in the United States

In our USA pharmacy, you can buy Miralax without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Miralax (polyethylene glycol 3350) is an osmotic laxative used for the relief of occasional constipation and to restore regular bowel movements. It works by retaining water in the stool, which softens the stool and increases the number of bowel movements by promoting a gentle, natural‑like laxation without harsh stimulant effects.
Usual adult dose: 17 grams (about one capful of the provided measuring cap) dissolved in 4‑8 ounces of a beverage once daily. The dose may be adjusted based on individual response but should not exceed 17 g per day unless directed by a physician.
Dosage form: Powder for oral solution (119 g bottle).
Onset of action: Bowel movement typically occurs within 1‑3 days of starting therapy.
Duration of action: Effects persist while taking the medication daily; bowel habit usually returns to baseline within a few days after discontinuation.
Alcohol consumption does not directly interact with polyethylene glycol 3350, but heavy intake can contribute to dehydration and may counteract the laxative effect. Moderate consumption is acceptable.
Most common side effects: abdominal bloating, gas, cramping, and mild diarrhea (usually transient and dose‑related).
Would you like to try Miralax without a prescription?

General Information about Miralax

• INN (International Nonproprietary Name): Polyethylene glycol 3350 (PEG 3350)
• Brand names available in the USA: Miralax® (Bayer HealthCare LLC). Numerous store‑brand and generic versions are also available over the counter, manufactured by companies such as Perrigo Company plc, LNK International, Inc., and others.
• ATC code: A06AD15
• Dosage forms and strengths: Powder for solution: 119 g and 238 g bottles. Each bottle cap, when filled to the marked line, provides approximately 17 g of PEG 3350 powder.
• Manufacturers in USA: Bayer HealthCare LLC (brand Miralax®); generic manufacturers include Perrigo Company plc, LNK International, Inc., and other FDA‑registered OTC producers.
• Registration status in USA: Approved as an over‑the‑counter (OTC) drug monograph product by the U.S. Food and Drug Administration (FDA).
• OTC / Rx classification: Over‑the‑counter (OTC) – no prescription required.

Mechanism of Action and Pharmacology

Polyethylene glycol 3350 is a high‑molecular‑weight (3350 Daltons), non‑absorbable, non‑metabolized polymer. After oral ingestion, it passes through the gastrointestinal tract without being absorbed into the bloodstream. It exerts its laxative effect through an osmotic mechanism: the polymer chains bind and retain water molecules via hydrogen bonding, increasing the water content of the stool. This hydrates, softens, and expands the stool mass, which distends the colon and stimulates stretch receptors, thereby triggering peristalsis and promoting a bowel movement. Unlike stimulant laxatives, PEG 3350 does not irritate the intestinal mucosa, alter electrolyte absorption, or produce tolerance. It is not fermented by colonic bacteria, so it produces minimal gas compared to fiber‑based laxatives. Because it is not absorbed, it has negligible systemic bioavailability, and any small amount that might be absorbed is excreted unchanged by the kidneys. The onset of action typically occurs within 24‑72 hours, making it suitable for gradual, predictable relief of constipation without urgency or cramping.

Indications

• Relief of occasional constipation (irregularity).
• Restoration of regular bowel movements.
• Short‑term treatment of constipation; generally recommended for no longer than 2 weeks without medical supervision.
• Off‑label but common use: bowel preparation before colonoscopy (at higher doses, often in combination with electrolytes), and management of chronic constipation under the guidance of a healthcare provider.

Important Warnings and Precautions

Miralax should not be used in patients with known or suspected bowel obstruction (ileus) or gastrointestinal perforation. If abdominal pain, nausea, vomiting, or rectal bleeding occurs, discontinue use and consult a physician immediately. Chronic, prolonged, or excessive use may lead to diarrhea with subsequent fluid and electrolyte loss; caution is advised in patients with renal impairment, as rare cases of osmotic nephrosis have been reported with high‑dose PEG preparations. Allergic reactions (rash, urticaria, angioedema) have been reported rarely. Discontinue use if hypersensitivity symptoms develop. When used for longer than one week, consider evaluation for underlying medical conditions. Keep out of reach of children; accidental ingestion may lead to aspiration or choking if powder is not properly dissolved. In elderly or debilitated patients, ensure adequate fluid intake to prevent dehydration.

At‑risk groups

• Elderly: No dose adjustment is required; however, elderly patients may be more susceptible to dehydration and electrolyte disturbances if diarrhea occurs. Encourage adequate fluid intake and short‑term use.
• Pregnancy: Polyethylene glycol 3350 is considered safe for occasional use during pregnancy. It is not absorbed systemically and is not expected to cause fetal harm. As with any medication during pregnancy, use only if clearly needed and consult a healthcare provider.
• Breastfeeding: PEG 3350 is not excreted into breast milk because it is not absorbed from the maternal gastrointestinal tract. It is considered compatible with breastfeeding.
• Renal impairment: Use with caution in patients with significant renal dysfunction, especially if high doses are used or prolonged therapy is required. Rare cases of osmotic nephrosis have been reported with large‑volume PEG preparations (e.g., colonoscopy bowel preparations), not with standard OTC doses, but monitoring is prudent.
• Hepatic impairment: No dose adjustment necessary; drug is not metabolized by the liver.
• Pediatric: Miralax is labeled for adults and children 17 years of age and older for OTC use. For younger children, use only under the advice of a physician. Dosing in children is weight‑based (typically 0.5‑1.5 g/kg/day); the OTC packaging should be used with caution and only as directed by a pediatrician.
• Fecal impaction or obstruction: Contraindicated; discontinue use if obstruction is suspected.

Driving and alcohol

Polyethylene glycol 3350 has no known effects on the central nervous system and does not impair the ability to drive or operate machinery. Alcohol consumption does not directly interact with the medication, but excessive alcohol intake may contribute to dehydration and may worsen constipation or fluid/electrolyte balance. Moderate alcohol consumption is acceptable while using Miralax.

Dosage Instructions

• Adults and adolescents 17 years of age and older: The recommended dose is 17 g once daily. Fill the measuring cap to the indicated line (approximately one capful) with powder. Stir the powder into 4‑8 ounces (120‑240 mL) of water, juice, soda, coffee, or tea until completely dissolved. Drink the entire solution immediately.
• Duration of use: Do not exceed 14 consecutive days without consulting a healthcare provider. If constipation persists after 7‑14 days of treatment, or if it recurs frequently, a physician should be consulted to rule out an underlying disorder.
• Administration: The powder can be dissolved in any cold or hot beverage; carbonated beverages may cause some effervescence. The solution should be consumed promptly after mixing; if not used immediately, it may be stored at room temperature and used within 24 hours. Stir again before drinking if separation occurs.
• Missed dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next daily dose, skip the missed dose and resume the usual schedule. Do not double the dose.
• Pediatric dosing (under 17 years, only under medical supervision): Dosing is weight‑based: typically 0.5‑1.5 grams per kilogram of body weight once daily, or as directed by a physician. The usual maximum daily dose for children is 17 g.

Side Effects and Contraindications

Most common side effects: Abdominal bloating, flatulence (gas), mild abdominal cramps or discomfort, and diarrhea (especially if the dose is too high). These are generally mild and resolve with continued use or dose reduction.
Less common but potentially serious: Severe diarrhea with resulting dehydration and electrolyte disturbances (particularly in elderly or debilitated patients); hypersensitivity reactions including rash, urticaria, pruritus, and angioedema; and anaphylaxis (very rare). Long‑term high‑dose use, such as in colonoscopy preparations, has been associated with acute phosphate nephropathy and osmotic nephrosis when electrolyte‑free solutions are used in large volumes.
Absolute contraindications: Known or suspected gastrointestinal obstruction or perforation; known hypersensitivity to polyethylene glycol or any component of the product.

Drug Interactions

• Other oral medications: Polyethylene glycol 3350 may theoretically reduce the gastrointestinal transit time and potentially decrease the absorption of other orally administered drugs if taken at the same time. To minimize this possibility, separate administration of Miralax from other oral medications by at least 2 hours.
• Electrolyte supplements and diuretics: No direct interaction, but if significant diarrhea occurs, electrolyte imbalances (hypokalemia, hyponatremia) could be exacerbated in patients taking diuretics or other electrolyte‑modifying agents. Maintain adequate hydration.
• Alcohol: No clinically significant interaction; moderate intake is acceptable.
• Polyethylene glycol 3350 is not absorbed and does not undergo hepatic metabolism; therefore, cytochrome P450‑mediated drug interactions are not expected.

Practical Advice

• Use the measuring cap provided with the bottle to ensure an accurate dose of 17 g (one capful to the marked line). Do not pack the powder into the cap; a loose, level fill is correct.
• Stir the powder into 4‑8 ounces of liquid until completely dissolved. The solution may be clear or slightly hazy. Drink it immediately after mixing for best taste and texture.
• Miralax can be taken at any time of the day, with or without food. Taking it at the same time each day may help establish a regular bowel routine.
• Bowel movement typically occurs 1‑3 days after the first dose. Do not take more than the recommended dose if a bowel movement does not occur immediately; exceeding the dose increases the risk of diarrhea and cramping.
• Drink plenty of clear fluids (water, juices, soups) throughout the day while taking Miralax to help the laxative work effectively and to prevent dehydration.
• If you experience severe abdominal pain, sudden change in bowel habits that lasts more than 2 weeks, or notice blood in your stools, discontinue use and consult a physician.
• Store the bottle tightly closed at room temperature (20‑25°C / 68‑77°F). Protect from excessive moisture. Keep out of reach of children.
• Do not use Miralax beyond the expiration date printed on the bottle. Discard any unused powder after the bottle has been opened for 1 year.
• Long‑term use of laxatives may lead to dependence and should be avoided unless under medical supervision. Use only for occasional constipation and not as a daily habit unless directed by a healthcare provider.

Alternative Medications

• Bisacodyl (Dulcolax®): A stimulant laxative that promotes bowel movements by directly stimulating the colon. Works faster (within 6‑12 hours orally, 15‑60 minutes rectally) but may cause cramping and is not recommended for daily long‑term use.
• Senna (Senokot®): A natural stimulant laxative derived from the senna plant. Stimulates intestinal contractions; onset in 6‑12 hours. Suitable for short‑term relief; may cause abdominal discomfort.
• Docusate sodium (Colace®): A stool softener that allows water and fats to penetrate the stool, softening it. Generally well‑tolerated but less effective than osmotic or stimulant laxatives for severe constipation.
• Lactulose: A synthetic disaccharide osmotic laxative available by prescription. Draws water into the colon and is fermented by bacteria, producing gas. Effective for chronic constipation but often causes bloating and flatulence.
• Magnesium hydroxide (Milk of Magnesia®): A saline osmotic laxative that works quickly (30 minutes to 6 hours). Suitable for occasional use; not recommended for patients with renal impairment due to magnesium accumulation.
• Psyllium fiber (Metamucil®): A bulk‑forming natural fiber supplement. Works by absorbing water and increasing stool bulk. Suitable for daily use to maintain regularity; requires adequate fluid intake to prevent obstruction.
• Lubiprostone (Amitiza®): A prescription chloride channel activator that increases intestinal fluid secretion. Indicated for chronic idiopathic constipation and opioid‑induced constipation in adults.

Clinical Efficacy

Polyethylene glycol 3350 has been extensively studied for the treatment of occasional and chronic constipation in adults and children. Multiple randomized, placebo‑controlled trials have demonstrated that PEG 3350 17 g once daily significantly increases stool frequency, softens stool consistency, and reduces straining compared with placebo, with a favorable tolerability profile. In a pivotal trial of 151 adults with constipation, PEG 3350 produced a bowel movement within 24‑48 hours in 50‑70% of subjects, with significant improvements in stool consistency scores. Long‑term studies of up to 6 months have shown sustained efficacy without evidence of tachyphylaxis or significant electrolyte disturbances at therapeutic doses. Compared to lactulose, PEG 3350 has been shown to be superior in improving stool frequency and consistency, with less gas production. PEG 3350 is recommended as a first‑line osmotic laxative by the American Gastroenterological Association and the American College of Gastroenterology for the treatment of chronic constipation. It is also a key component of bowel preparation regimens before colonoscopy, typically used in high doses (238 g or more) with electrolytes, a testament to its excellent safety record even at larger doses.

Important:

Miralax (polyethylene glycol 3350) is an over‑the‑counter osmotic laxative that should be used only for the temporary relief of occasional constipation. Do not use this product for more than 14 consecutive days without consulting a physician. If you experience severe abdominal pain, nausea, vomiting, bloating that does not resolve, or if you notice blood in your stools, stop using Miralax and seek medical attention immediately. Do not use if you have a known or suspected bowel obstruction or an allergy to polyethylene glycol. Prolonged or excessive use may lead to diarrhea, dehydration, and electrolyte imbalances. Use with caution in patients with renal impairment and in the elderly; maintain adequate fluid intake. Keep out of reach of children. In the event of an accidental overdose, contact a poison control center or seek emergency medical care. If constipation persists or recurs frequently, consult your healthcare provider to rule out an underlying medical condition. This medication is not a substitute for a healthy diet rich in fiber, regular fluid intake, and physical activity. Pregnant and breastfeeding women should consult their healthcare provider before use, although the product is generally considered safe during these periods. Always follow the label directions and never share the measuring cap between different products or people.

How to buy Generic Miralax no prescription U.S. Online Pharmacy